Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up

References

• Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690–697.
   PubMed Web of Science ®Google Scholar
• Jussila A, Virta LJ, Kautiainen H, et al. Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. Inflamm Bowel Dis. 2012;18:555–561.
   PubMed Web of Science ®Google Scholar
• Da W, Zhu J, Wang L, et al. Adalimumab for Crohn’s disease after infliximab treatment failure: a systematic review. Eur J Gastroenterol Hepatol. 2013;25:885–891.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, van Assche G, Sandborn W, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102–1111.
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287–296.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–413.
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho J. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–1635.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL, Binion DG, et al. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267–276.
   PubMed Web of Science ®Google Scholar
• Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9:806–815.
   PubMed Web of Science ®Google Scholar
• Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909–1915.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Feagan B, Lichtenstein G, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Christensen KR, Steenholdt C, Brynskov J. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study. Scand J Gastroenterol. 2015;50:1018–1024.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–838.
   PubMed Web of Science ®Google Scholar
• Baki E, Zwickel P, Zawierucha A, et al. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World J Gastroenterol. 2015;21:3282–3290.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2:542–553.
   PubMed Web of Science ®Google Scholar
• Molander P, Färkkilä M, Salminen K, et al. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis. 2014;20:1021–1028.
   PubMed Web of Science ®Google Scholar
• Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut. 2014;63:1607–1616.
   PubMed Web of Science ®Google Scholar
• Bridger S, Lee JC, Bjarnason I, et al. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn’s disease and non-smokers develop ulcerative colitis. Gut. 2002;51:21–25.
   PubMed Web of Science ®Google Scholar
• Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci. 1989;34:1841–1854.
   PubMed Web of Science ®Google Scholar
• Lunney PC, Kariyawasam VC, Wang RR, et al. Smoking prevalence and its influence on disease course and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2015;42:61–70.
   PubMed Web of Science ®Google Scholar
• De Bie C, Ballet V, Hendriks N, et al. Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42:1294–1302.
   PubMed Web of Science ®Google Scholar
• Biedermann L, Fournier N, Misselwitz B, et al. High rates of smoking especially in female Crohn’s disease patients and low use of supportive measures to achieve smoking cessation-data from the Swiss IBD Cohort Study. J Crohn’s Colitis. 2015;9:819–829.
   Google Scholar
• Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:74–80.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Ferrante M, Vermeire S, et al. Faecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kärkkäinen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221–1229.
   PubMed Web of Science ®Google Scholar
• Smith L, Gaya D. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol. 2012;18:6782–6789.
   PubMed Web of Science ®Google Scholar